Amgen Talks Dual Pricing Strategy For Amjevita
Debut US Humira Biosimilar Has Been Priced To Address ‘Complexity Of The US Market’
Executive Summary
In the wake of Amgen announcing a dual pricing strategy for its debut US adalimumab biosimilar – with the firm’s newly-launched Amjevita version being offered at both 5% off and 55% off the WAC of the Humira original – investors and analysts were keen to press the firm for further details of its pricing strategy.
You may also be interested in...
US Amjevita Sales Slide By Almost Two-Thirds
Amgen has revealed a significant – albeit expected – drop in second-quarter sales figures for its Amjevita US biosimilar rival to Humira.
Savvy Pricing Practices Enabling Deep Discounts For Adalimumab And Glargine
The second quarterly report on the biosimilars industry from Samsung Bioepis has drawn attention to how pricing strategies are being used to enable discounts for adalimumab and insulin glargine.
US Biosimilars Need Access In Exchange For Industry Commitment
As the dust settles after a wave of fresh adalimumab biosimilar launches, the US Biosimilars Forum’s executive director Julie Reed talks to Generics Bulletin about how other stakeholders need to step up to meet industry’s commitment to the sector – as well as how PBMs are distorting the market and streamlined regulation is needed to drive competition.